Penicillin G sodium salt (Powder) Instructions for Use
Marketing Authorization Holder
Biochemie GmbH (Austria)
ATC Code
J01CE01 (Benzylpenicillin)
Active Substance
Benzylpenicillin (Rec.INN registered by WHO)
Dosage Form
| Penicillin G sodium salt | Powder for solution for injection 1 million IU: fl. 100 pcs. |
Dosage Form, Packaging, and Composition
| Powder for solution for injection | 1 vial |
| Benzylpenicillin sodium salt | 1 million IU |
Vials (100) – cardboard boxes.
Clinical-Pharmacological Group
Penicillin antibiotic, destroyed by penicillinase
Pharmacotherapeutic Group
Antibiotic, penicillin
Pharmacological Action
An antibiotic from the group of biosynthetic penicillins. It exerts a bactericidal effect by inhibiting the synthesis of the microorganism’s cell wall.
It is active against gram-positive bacteria: Staphylococcus spp., Streptococcus spp. (including Streptococcus pneumoniae), Corynebacterium diphtheriae, Bacillus anthracis; gram-negative bacteria: Neisseria gonorrhoeae, Neisseria meningitidis; anaerobic spore-forming rods; as well as Actinomyces spp., Spirochaetaceae.
Strains of Staphylococcus spp. that produce penicillinase are resistant to the action of benzylpenicillin. It is destroyed in an acidic environment.
The procaine salt of benzylpenicillin is characterized by a longer duration of action compared to the potassium and sodium salts.
Pharmacokinetics
After intramuscular administration, it is rapidly absorbed from the injection site. It is widely distributed in body tissues and fluids. Benzylpenicillin penetrates well through the placental barrier and the blood-brain barrier when the meninges are inflamed.
T1/2 is 30 minutes. It is excreted in the urine.
Indications
Treatment of diseases caused by microorganisms sensitive to benzylpenicillin: lobar and focal pneumonia, pleural empyema, sepsis, septicemia, pyemia, acute and subacute septic endocarditis, meningitis, acute and chronic osteomyelitis, infections of the urinary and biliary tracts, tonsillitis, purulent infections of the skin, soft tissues and mucous membranes, erysipelas, diphtheria, scarlet fever, anthrax, actinomycosis, treatment of purulent-inflammatory diseases in obstetric and gynecological practice, ENT diseases, eye diseases, gonorrhea, blennorrhea, syphilis.
ICD codes
| ICD-10 code | Indication |
| A22 | Anthrax |
| A36 | Diphtheria |
| A38 | Scarlet fever |
| A40 | Streptococcal sepsis |
| A41 | Other sepsis |
| A42 | Actinomycosis |
| A46 | Erysipelas |
| A50 | Congenital syphilis |
| A51 | Early syphilis |
| A52 | Late syphilis |
| A54 | Gonococcal infection |
| A54.3 | Gonococcal eye infection |
| G00 | Bacterial meningitis, not elsewhere classified |
| H10 | Conjunctivitis |
| H15.0 | Scleritis |
| H15.1 | Episcleritis |
| H16 | Keratitis |
| H20 | Iridocyclitis |
| H66 | Suppurative and unspecified otitis media |
| I33 | Acute and subacute endocarditis |
| J01 | Acute sinusitis |
| J02 | Acute pharyngitis |
| J03 | Acute tonsillitis |
| J04 | Acute laryngitis and tracheitis |
| J15 | Bacterial pneumonia, not elsewhere classified |
| J20 | Acute bronchitis |
| J31 | Chronic rhinitis, nasopharyngitis and pharyngitis |
| J32 | Chronic sinusitis |
| J35.0 | Chronic tonsillitis |
| J37 | Chronic laryngitis and laryngotracheitis |
| J42 | Unspecified chronic bronchitis |
| J86 | Pyothorax (pleural empyema) |
| K81.0 | Acute cholecystitis |
| K81.1 | Chronic cholecystitis |
| K83.0 | Cholangitis |
| L01 | Impetigo |
| L02 | Cutaneous abscess, furuncle and carbuncle |
| L03 | Cellulitis |
| L08.0 | Pyoderma |
| L08.8 | Other specified local infections of skin and subcutaneous tissue |
| M86 | Osteomyelitis |
| N10 | Acute tubulointerstitial nephritis (acute pyelonephritis) |
| N11 | Chronic tubulointerstitial nephritis (chronic pyelonephritis) |
| N30 | Cystitis |
| N34 | Urethritis and urethral syndrome |
| N41 | Inflammatory diseases of prostate |
| N70 | Salpingitis and oophoritis |
| N71 | Inflammatory disease of uterus, excluding cervix (including endometritis, myometritis, metritis, pyometra, uterine abscess) |
| N72 | Inflammatory disease of cervix uteri (including cervicitis, endocervicitis, exocervicitis) |
| N73.5 | Unspecified female pelvic peritonitis |
| T79.3 | Posttraumatic wound infection, not elsewhere classified |
| ICD-11 code | Indication |
| 1A60.Z | Congenital syphilis, unspecified |
| 1A61.Z | Early syphilis, unspecified |
| 1A62.Z | Late syphilis, unspecified |
| 1A72.4 | Gonococcal eye infection |
| 1A7Z | Gonococcal infection, unspecified |
| 1B50 | Scarlet fever |
| 1B70.0Z | Erysipelas, unspecified |
| 1B70.1 | Streptococcal cellulitis of the skin |
| 1B70.2 | Staphylococcal cellulitis of the skin |
| 1B70.Z | Bacterial cellulitis or lymphangitis caused by unspecified bacterium |
| 1B72.0 | Bullous impetigo |
| 1B72.1 | Nonbullous impetigo |
| 1B72.Z | Impetigo, unspecified |
| 1B75.0 | Furuncle |
| 1B75.1 | Carbuncle |
| 1B75.2 | Furunculosis |
| 1B75.3 | Pyogenic skin abscess |
| 1B7Y | Other specified pyogenic bacterial infections of skin or subcutaneous tissue |
| 1B97 | Anthrax |
| 1C10.Z | Actinomycosis, unspecified |
| 1C17.Z | Diphtheria, unspecified |
| 1C44 | Non-pyogenic bacterial infections of skin |
| 1D01.0Z | Bacterial meningitis, unspecified |
| 1G40 | Sepsis without septic shock |
| 9A60.Z | Conjunctivitis, unspecified |
| 9A71 | Infectious keratitis |
| 9A7Z | Diseases of the cornea, unspecified |
| 9A96.0 | Anterior uveitis, not associated with systemic diseases |
| 9A96.1 | Anterior uveitis, associated with systemic diseases |
| 9A96.Z | Anterior uveitis, unspecified |
| 9B50 | Episcleritis |
| 9B51 | Scleritis |
| AA9Z | Unspecified suppurative otitis media |
| BB4Z | Acute or subacute endocarditis, unspecified |
| CA01 | Acute rhinosinusitis |
| CA02.Z | Acute pharyngitis, unspecified |
| CA03.Z | Acute tonsillitis, unspecified |
| CA05 | Acute laryngitis or tracheitis |
| CA09 | Chronic rhinitis, nasopharyngitis or pharyngitis |
| CA0A.Z | Chronic rhinosinusitis, unspecified |
| CA0F.Y | Other specified chronic diseases of the palatine tonsils and adenoids |
| CA0G | Chronic laryngitis or laryngotracheitis |
| CA20.1Z | Chronic bronchitis, unspecified |
| CA40.0Z | Bacterial pneumonia, unspecified |
| CA42.Z | Acute bronchitis, unspecified |
| CA44 | Pyothorax |
| DC12.0Z | Acute cholecystitis, unspecified |
| DC12.1 | Chronic cholecystitis |
| DC13 | Cholangitis |
| EA50.3 | Staphylococcal scarlet fever |
| EB21 | Pyoderma gangrenosum |
| FB84.Z | Osteomyelitis or osteitis, unspecified |
| GA01.Z | Inflammatory diseases of uterus, except cervix, unspecified |
| GA05.2 | Unspecified pelvic peritonitis in women |
| GA07.Z | Salpingitis and oophoritis, unspecified |
| GA91.Z | Inflammatory and other diseases of prostate, unspecified |
| GB50 | Acute tubulo-interstitial nephritis |
| GB51 | Acute pyelonephritis |
| GB55.Z | Chronic tubulo-interstitial nephritis, unspecified |
| GB5Z | Renal tubulo-interstitial diseases, unspecified |
| GC00.Z | Cystitis, unspecified |
| GC02.Z | Urethritis and urethral syndrome, unspecified |
| NF0A.3 | Posttraumatic wound infection, not elsewhere classified |
| GA0Z | Inflammatory diseases of female genital tract, unspecified |
| XA5WW1 | Cervix uteri |
Dosage Regimen
| The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen. |
Individual. It is administered intramuscularly, intravenously, subcutaneously, endolumbally.
For intramuscular and intravenous administration in adults, the daily dose ranges from 250,000 to 60 million IU. The daily dose for children under 1 year of age is 50,000-100,000 IU/kg, over 1 year – 50,000 IU/kg; if necessary, the daily dose can be increased to 200,000-300,000 IU/kg, for vital indications – up to 500,000 IU/kg. The frequency of administration is 4-6 times/day.
For endolumbar administration, depending on the disease and severity of the course, adults are given 5,000-10,000 IU, children – 2,000-5,000 IU. The drug is diluted in sterile water for injection or in 0.9% sodium chloride solution at the rate of 1 thousand IU/ml. Before injection (depending on the level of intracranial pressure), 5-10 ml of cerebrospinal fluid is withdrawn and added to the antibiotic solution in an equal ratio.
Subcutaneously, Benzylpenicillin is used for infiltrate injections (100,000-200,000 IU in 1 ml of 0.25%-0.5% procaine solution).
Benzylpenicillin potassium salt is used only intramuscularly and subcutaneously, in the same doses as benzylpenicillin sodium salt.
Benzylpenicillin procaine salt is used only intramuscularly. The average therapeutic dose for adults: single – 300,000 IU, daily – 600,000 IU. For children under 1 year of age – 50,000-100,000 IU/kg/day, over 1 year – 50,000 IU/kg/day. The frequency of administration is 3-4 times/day.
The duration of treatment with benzylpenicillin, depending on the form and severity of the disease, can range from 7-10 days to 2 months or more.
Adverse Reactions
From the digestive system diarrhea, nausea, vomiting.
Effects due to chemotherapeutic action vaginal candidiasis, oral candidiasis.
From the central nervous system when using benzylpenicillin in high doses, especially with endolumbar administration, neurotoxic reactions may develop: nausea, vomiting, increased reflex excitability, meningism symptoms, convulsions, coma.
Allergic reactions increased body temperature, urticaria, skin rash, rash on mucous membranes, joint pain, eosinophilia, angioedema. Cases of anaphylactic shock with fatal outcome have been described.
Contraindications
Hypersensitivity to benzylpenicillin and other drugs from the group of penicillins and cephalosporins. Endolumbar administration is contraindicated in patients suffering from epilepsy.
Use in Pregnancy and Lactation
Use during pregnancy is possible only if the intended therapeutic benefit for the mother outweighs the potential risk to the fetus.
If use during lactation is necessary, the issue of discontinuing breastfeeding should be decided.
Use in Renal Impairment
Use with caution in patients with impaired renal function.
Pediatric Use
Can be used in children according to indications.
Special Precautions
Use with caution in patients with impaired renal function, heart failure, predisposition to allergic reactions (especially drug allergy), and with hypersensitivity to cephalosporins (due to the possibility of cross-allergy).
If no effect is observed 3-5 days after the start of use, a switch to other antibiotics or combination therapy should be made.
Due to the possibility of fungal superinfection, it is advisable to prescribe antifungal drugs during treatment with benzylpenicillin.
It must be taken into account that the use of benzylpenicillin in subtherapeutic doses or premature discontinuation of treatment often leads to the emergence of resistant strains of pathogens.
Drug Interactions
Probenecid reduces the tubular secretion of benzylpenicillin, resulting in an increase in its plasma concentration and an increase in the half-life.
With simultaneous use with antibiotics that have a bacteriostatic effect (tetracycline), the bactericidal effect of benzylpenicillin is reduced.
Storage Conditions
Store at 2°C (36°F) to 25°C (77°F). Keep in original packaging, protected from light. Keep out of reach of children.
Dispensing Status
Rx Only
Important Safety Information
This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.
Medical Disclaimer
Actovegin pills 200mg, 50pcs
Noopept, pills 10mg, 50pcs
Kagocel pills 12mg, 30pcs
Ingavirin capsules 90mg, 10pcs
Cortexin, 10mg, 5ml, 10pcs
Belosalic, lotion solution for external use spray 100ml 